Stabilization of eye drops containing autologous serum and recombinant human epidermal growth factor for dry eye syndrome

Sriwidodo, Sriwidodo; Syah, Insan Sunan Kurniawan; Maksum, Iman Peramana; Subroto, Toto; Zasvia, Ulvi; Umar, Abd. Kakhar

doi:10.4103/japtr.japtr_72_20

Cited by 6 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may represent an obstacle for their use in the office setting and for their regulatory compliance. As a consequence, recent efforts have been focused into lyophilizing blood derived products for easier preservation and ambient storage [ 37 , 38 , 39 ]. However, these studies did not use UCBS but rather AS and plasma rich in growth factors (PRGF).…”

Section: Discussionmentioning

confidence: 99%

Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases

Tovar

White²,

Sabater

2021

Medicines

View full text Add to dashboard Cite

Blood derived products have become a valuable source of tissue for the treatment of ocular surface diseases that are refractory to conventional treatments. These can be obtained from autologous or allogeneic sources (patient’s own blood or from healthy adult donors/umbilical cord blood, respectively). Allogeneic cord blood demonstrates practical advantages over alternatives and these advantages will be discussed herein. Umbilical cord blood (UCB) can be divided, generally speaking, into two distinct products: first, mononuclear cells, which can be used in regenerative ophthalmology, and second, the plasma/serum (an acellular fraction), which may be used in the form of eyedrops administered directly to the damaged ocular surface. The rationale for using umbilical cord serum (UCS) to treat ocular surface diseases such as severe dry eye syndrome (DES), persistent epithelial defects (PED), recurrent epithelial erosions, ocular chemical burns, graft versus host disease (GVHD), among others, is the considerably high concentration of growth factors and cytokines, mimicking the natural healing properties of human tears. Allogeneic serum also offers the opportunity for therapeutic treatment to patients who, due to poor heath, cannot provide autologous serum. The mechanism of action involves the stimulation of endogenous cellular proliferation, differentiation and maturation, which is highly efficient in promoting and enhancing corneal epithelial healing where other therapies have previously failed.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases

Tovar

White²,

Sabater

2021

Medicines

View full text Add to dashboard Cite

show abstract

“…They are usually indicated 4-6 times per day, and as most people work or spend an important part of the day out of their homes, it can be difficult to carry around these products compared to conventional ATs that do not require refrigeration. For this reason, a more practical version in terms of storage and use is urgently needed, more so for patients for whom long-term therapy is required [87]. However, in 2020 three studies (one using PRGF [78] and two ASTs [87,88]) demonstrated that the concentration of GFs remained stable for up to 3 months [78,87,88] after lyophilization.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

“…For this reason, a more practical version in terms of storage and use is urgently needed, more so for patients for whom long-term therapy is required [87]. However, in 2020 three studies (one using PRGF [78] and two ASTs [87,88]) demonstrated that the concentration of GFs remained stable for up to 3 months [78,87,88] after lyophilization. Lyophilization is a method of dehydration that involves freezing a product and removing the frozen water through sublimation.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Untitled

2021

OCR

View full text Add to dashboard Cite

Background and RationaleAutologous, meaning self, blood derivate products have been used to treat several ocular surface pathologic conditions for more than four decades now. They were first mentioned in ophthalmologic-related literature in 1975, when a mobile ocular perfusion pump containing a patient's autologous serum was used to treat conditions such as Stevens-Johnson Syndrome (SJS), ocular pemphigoid, Keratoconjunctivitis Sicca (KCS), chemical burns, and Persistent Epithelial Defects (PED),

show abstract

Autologous Blood Products: When, Where, and How?

Tovar

Sabater

2021

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Stabilization of eye drops containing autologous serum and recombinant human epidermal growth factor for dry eye syndrome

Cited by 6 publications

References 15 publications

Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases

Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases

Untitled

Autologous Blood Products: When, Where, and How?

Contact Info

Product

Resources

About